Has Johnson & Johnson (JNJ) Run Too Far After A 54% One-Year Surge?

Simply Wall St.05-17

Wondering if Johnson & Johnson at around US$226.71 is still a fair deal, or if the stock has already run too far for comfort. The stock closed at US$226.71, with a 2.4% gain over the last week, a 9.3%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636930060?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625","is_english":true,"pubTime":"2026-05-17 11:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636930060","market":"hk","top_or_hot":-1,"title":"Has Johnson & Johnson (JNJ) Run Too Far After A 54% One-Year Surge?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Johnson & Johnson at around US$226.71 is still a fair deal, or if the stock has already run too far for comfort. The stock closed at US$226.71, with a 2.4% gain over the last week, a 9.3%...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/has-johnson-johnson-jnj-run-too-far-after-a-54-one-year-surg\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Has Johnson & Johnson (JNJ) Run Too Far After A 54% One-Year Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHas Johnson & Johnson (JNJ) Run Too Far After A 54% One-Year Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-17 11:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/has-johnson-johnson-jnj-run-too-far-after-a-54-one-year-surg><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Johnson & Johnson at around US$226.71 is still a fair deal, or if the stock has already run too far for comfort. The stock closed at US$226.71, with a 2.4% gain over the last week, a 9.3%...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/has-johnson-johnson-jnj-run-too-far-after-a-54-one-year-surg\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0426412945.USD","symbol_name":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/has-johnson-johnson-jnj-run-too-far-after-a-54-one-year-surg","article_id":"2636930060","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/139677-main-header/1756253951625"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-jnj/johnson-johnson/news/has-johnson-johnson-jnj-run-too-far-after-a-54-one-year-surg","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2636930060","pubTimestamp":1778988960,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Johnson & Johnson at around US$226.71 is still a fair deal, or if the stock has already run too far for comfort.\nThe stock closed at US$226.71, with a 2.4% gain over the last week, a 9.3% gain year to date, and a 54.0% gain over the last year. The past month shows a 3.2% decline that may reflect some cooling or a shift in risk appetite.\nRecent headlines have focused on Johnson & Johnson's ongoing product portfolio, legal developments, and healthcare sector trends. These factors...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE000MB6IJN5.SGD":"RQI GLOBAL \"I\" (SGD) ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4585":"ETF&股票定投概念","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU2471134523.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","JNJ":"强生","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU2213496289.HKD":"ALLIANZ INCOME AND GROWTH \"AT\" (HKD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4550":"红杉资本持仓","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE000F7OJYX1.SGD":"RQI GLOBAL \"I\" (SGDHDG) INC","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","BK4581":"高盛持仓","IE0000B7K699.USD":"RQI GLOBAL \"I\" (USD) INC","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC"},"translate_title":"强生公司(JNJ)在一年内飙升54%后是否走得太远了？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1.5,"DCF":1},"content_text":"Wondering if Johnson & Johnson at around US$226.71 is still a fair deal, or if the stock has already run too far for comfort. The stock closed at US$226.71, with a 2.4% gain over the last week, a 9.3% gain year to date, and a 54.0% gain over the last year. The past month shows a 3.2% decline that may reflect some cooling or a shift in risk appetite. Recent headlines have focused on Johnson & Johnson's ongoing product portfolio, legal developments, and healthcare sector trends. These factors continue to shape how investors think about the stock and help explain why the share price has moved between periods of strength and short term pullbacks. Right now Johnson & Johnson holds a valuation score of 3/6, which means it screens as undervalued on half of Simply Wall St's standard checks. The next sections break that down using several valuation approaches and finish with a framework that can help you interpret those signals more clearly.  Johnson & Johnson delivered 54.0% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. AdvertisementApproach 1: Johnson & Johnson Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes projections of the cash a company may generate in the future and discounts those cash flows back to today using a required rate of return. The idea is to estimate what all those future dollars are worth in present terms. For Johnson & Johnson, the model used here is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $17.0b. Analyst inputs are provided for several future years, and Simply Wall St then extrapolates further free cash flow out to 2035, with 2030 projected at $35.9b. All figures are in $. On this basis, the DCF model arrives at an estimated intrinsic value of about $374.05 per share. Compared with the recent share price of $226.71, the model suggests an implied discount of roughly 39.4%, which screens as undervalued on this measure. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Johnson & Johnson is undervalued by 39.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks. JNJ Discounted Cash Flow as at May 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Johnson & Johnson. Approach 2: Johnson & Johnson Price vs Earnings The P/E ratio is a common way to value a profitable company because it ties what you pay for the stock to the earnings it currently generates. In general, higher growth expectations and lower perceived risk can justify a higher P/E. In contrast, slower growth or higher risk can point to a lower, more cautious multiple. Johnson & Johnson currently trades on a P/E of 25.94x. That is above the Pharmaceuticals industry average P/E of 14.78x and slightly above the peer group average of 25.39x. Simply Wall St also calculates a proprietary “Fair Ratio” of 28.41x, which is the P/E level suggested by factors such as Johnson & Johnson's earnings profile, industry, profit margins, market capitalization and risk characteristics. This Fair Ratio is more tailored than a simple peer or industry comparison because it builds in company specific traits like growth outlook, profitability and risk, rather than assuming all stocks in the same industry deserve the same multiple. With the current P/E of 25.94x sitting below the Fair Ratio of 28.41x, the stock screens as slightly undervalued on this measure. Result: UNDERVALUED NYSE:JNJ P/E Ratio as at May 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Johnson & Johnson Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to attach a clear story about Johnson & Johnson to the numbers, linking your view on its future revenue, earnings and margins to a fair value estimate that sits inside Simply Wall St's Community page, updates automatically when fresh news or earnings arrive, and can guide your decisions by comparing that fair value to the current price, whether you lean closer to a higher fair value like US$265.00, a lower one around US$181.77, or something in between such as US$246.46 or US$230.82. For Johnson & Johnson, however, we will make it really easy for you with previews of two leading Johnson & Johnson Narratives: 🐂 Johnson & Johnson Bull Case Fair value in this narrative: US$252.96 per share Implied discount vs last close: around 10.4% below this fair value Revenue growth assumption: 6.54% a year  Analysts expect the drug portfolio and pipeline, especially in immunology and oncology, to support higher revenue over time while Johnson & Johnson invests heavily in U.S. manufacturing, R&D and MedTech capacity. Assumptions include earnings rising from about US$21.0b today to US$26.9b by around May 2029, with profit margins edging up and the stock trading on a P/E of 27.8x, above the current U.S. Pharmaceuticals industry level cited at 15.3x. Risks focus on loss of exclusivity for key products like STELARA, tariff pressures and ongoing litigation, which could affect revenue, margins and cash flow if outcomes are less favorable than analysts currently build into their models.  🐻 Johnson & Johnson Bear Case Fair value in this narrative: US$173.55 per share Implied premium vs this fair value: around 30.6% above this level Revenue growth assumption: 6.3% a year  This narrative highlights a well diversified late stage drug pipeline and the Kenvue spin off, which leaves Johnson & Johnson more focused on Medical Devices and Pharmaceuticals but also more dependent on successful drug approvals and adoption. Assumptions include revenue growing from a US$84.0b baseline to about US$120.6b by 2028, profit margins around 20% and ongoing share buybacks reducing the share count by about 2% a year, supporting capital returns alongside the dividend. Key concerns are unresolved lawsuits, patent expiries for major drugs and uncertainty around how much of the pipeline ultimately turns into profitable products, leading this narrative to a lower fair value estimate than the recent share price.  If these two narratives feel like a useful framework, you can go deeper into the underlying assumptions, risks and valuation methods, or compare them with other community views, to decide which story of Johnson & Johnson lines up more closely with your own expectations for the stock over the next several years. See what the community is saying about Johnson & Johnson Do you think there's more to the story for Johnson & Johnson? Head over to our Community to see what others are saying! NYSE:JNJ 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636930060","isCrawlerRequest":true}